Clinical utility of neuroprotective agents in neurodegenerative diseases: Current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic...

by Dunkel, P., Chai, C.L., Sperlágh, B., Huleatt, P.B., Mátyus, P.
Published 2014

Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease

by Baranyi M., Porceddu P.F., Gölöncsér F., Kulcsár S., Otrokocsi L., Kittel Á., Pinna A., Frau L., Huleatt P.B., Khoo M.-L., Chai C.L.L., Dunkel P., Mátyus P., Morelli M., Sperlágh B.
Published 2018